3 unknown, 2 not yet recruiting, 2 recruiting, 1 terminated. 6 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 3, Recruiting 2, Terminated 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow pMMR: new trials by email Literature Review of pMMR trials Research Report on pMMR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER DNA methylation profiles - Endometrial Carcinoma (EC), pMMR | Not applicable | Not yet recruiting | European Institute of Oncology | 50 | 2026-01-21 | 2026-01-29 |
| SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases short-course radiotherapy, CAPEOX/XELOX, Serplulimab - Colorectal Carcinoma, Oligometastases | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 51 | 2025-04-22 | 2026-03-25 |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Serplulimab, Capecitabine, Oxaliplatin - pMMR, MSS | Phase 2 | Recruiting | Zhejiang University | 50 | 2023-02-22 | 2026-03-05 |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer Atezolizumab, Therasphere, XELOX - Metastatic Colorectal Cancer, pMMR | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 52 | 2020-10-07 | 2023-08-18 |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer Bevacizumab, Tripleitriumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2020-09-20 | 2020-09-17 |
| Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. TKI ± anti-PD-1 antibody - MSS, pMMR | Phase 2 | Unknown | China Medical University, China | 53 | 2020-07-24 | 2021-10-05 |
Colorectal Neoplasms (4) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Rectal Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Colonic Diseases (5) · Rectal Diseases (5) · Colorectal Neoplasms (2) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1)
Bevacizumab (3) · XELOX (2) · atezolizumab (2) · Capecitabine (1) · Celecoxib (1) · Drug Therapy (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy (1) · Oxaliplatin (1) · Surgical Procedures, Operative (1)
China Medical University, China (1) · European Institute of Oncology (1) · Federation Francophone de Cancerologie Digestive (1) · First Affiliated Hospital of Zhejiang University (1) · Fudan University (1) · Replimune, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Zhejiang University (1)
China (5) · France (1) · Italy (1) · United States (1)
Gary Vanasse, MD (1) · Jingdong Zhang (1) · Sanjun Cai, MD (1) · Ying Yuan, M.D. (1) · Zhen Zhang, MD (1)